Wird geladen...
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab
BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor-2 (HER2). Cardiotoxicity is a potential adverse effect, manifesting as either an asymptomatic decline in left-ventricular ejection fraction or infrequently as largely reversible symptomatic heart failure (HF). Monitoring reco...
Gespeichert in:
| Veröffentlicht in: | Ann Pharmacother |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4983504/ https://ncbi.nlm.nih.gov/pubmed/27307412 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1060028016654160 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|